Meyka Pro banner
B&K Corporation Limited

B&K Corporation Limited (2396.HK) Stock Competitors & Peer Comparison

See (2396.HK) competitors and their performances in Stock Market.

2396.HKHKSE
HealthcareBiotechnology
HK$3.90
HK$0.00(0.00%)
Hong Kong Market is Open · 14:22

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2396.HKHK$3.75-0.27%322.1M-1.61-HK$2.41N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$193.50+4.26%258.3B86.58HK$2.21N/A
1801.HKHK$92.50+3.99%161B170.10HK$0.54N/A
2269.HKHK$39.04+5.57%158.5B29.94HK$1.28N/A
6990.HKHK$510.00+4.85%117.5B-249.87-HK$2.02N/A
9926.HKHK$93.90+6.28%85.9B-69.59-HK$1.34N/A
3347.HKHK$37.48+2.13%46.4B39.10HK$0.98+0.38%
6821.HKHK$123.40+5.29%43.7B39.67HK$3.05+1.24%
1530.HKHK$16.84+4.27%43B4.48HK$3.84+1.46%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2396.HK vs 4332.HK Comparison July 2026

2396.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2396.HK stands at 322.1M. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2396.HK is priced at HK$3.75, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2396.HK currently has a P/E ratio of -1.61, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2396.HK's ROE is N/A, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2396.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2396.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions